Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Completed · Phase 3 · Has a placebo group

Conditions studied: Major Depressive Disorder

In brief

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.

Key facts

Study ID

NCT04985942

Run by

Intra-Cellular Therapies, Inc.

People needed

485

Starts

2021-07-30

Expected to finish

2024-02-27

Last updated by the study team

2025-05-02

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female patients between the ages of 18 and 65 years, inclusive;
• Meet DSM-5 diagnostic criteria for MDD (a diagnosis of MDD with psychotic features will be acceptable) as confirmed by the Investigator or Sponsor-approved rater using the Mini-International Neuropsychiatric Interview (MINI), and meet all the following criteria:
• The start of the current major depressive episode (MDE) is at least 8 weeks but not more than 18 months prior to Screening;
• Has at least moderate severity of illness based on rater-administered MADRS total score ≥ 24 at Screening and at Baseline;
• Has at least moderate severity of illness based on CGI-S score ≥ 4 at Screening and at Baseline;
• Has a Quick Inventory of Depressive Symptomatology-Self Report-16 item (QIDS-SR-16) score ≥14 at Screening and at Baseline;
• Has sufficient history and medical record confirmation verifying the ADT and the current MDE is causing clinically significant distress or impairment in social, occupational, or other important areas of functioning.
• Currently having an inadequate response to ADT (less than 50% improvement) as confirmed by the Investigator and taking at least the minimum effective dose (per package insert) of one of the following antidepressants as monotherapy treatment for at least 6 weeks duration:
• citalopram/escitalopram
• fluoxetine
• paroxetine
• sertraline
• duloxetine
• levomilnacipran/milnacipran (if locally approved for MDD)
• venlafaxine/desvenlafaxine
• buproprion
• vilazodone
• vortioxetine

You may not qualify if…

• Within the patient's lifetime, has a confirmed DSM-5 psychiatric diagnosis other than MDD, including:
• Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder or other psychotic disorder;
• Bipolar Disorder;
• Within 6 months of Screening, has a confirmed DSM-5 psychiatric diagnosis other than MDD including:
• Anxiety disorders such as Panic Disorder or Generalized Anxiety Disorder; Obsessive-compulsive Disorder; Posttraumatic Stress Disorder as primary diagnoses.
• Eating disorder;
• Substance use disorders (excluding nicotine);
• Personality disorder of sufficient severity to have a major impact on the patient's psychiatric status;
• Within 12 months of Screening, has had any other psychiatric condition (other than MDD) that has been the main focus of treatment;
• The patient experiences a ≥ 25% decrease in the MADRS total score between Screening and Baseline;
• The patient experiences a ≥ 25% decrease in the QIDS-SR-16 total score between Screening and Baseline;
• In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during participation in the study or:
• At Screening, the patient scores "yes" on Suicidal Ideation Items 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to Screening, or at Baseline, the patient scores "yes" on Suicidal Ideation Items 4 or 5 since the Screening Visit;
• At Screening, the patient has had 1 or more suicide attempts within 2 years prior to Screening;
• At Screening or Baseline, the patient scores ≥ 5 on MADRS Item 10 (Suicidal Thoughts), or
• The patient is considered to be in imminent danger to him/herself or others.
• The patient has a first MDE at age 60 years or older.

Where it is running

• Clinical Site — Cedarhurst, New York, United States
• Clinical Site — Phoenix, Arizona, United States
• Clinical Site — Glendale, California, United States
• Clinical Site — Oceanside, California, United States
• Clinical Site — Redlands, California, United States
• Clinical Site — Temecula, California, United States
• Clinical Site — Upland, California, United States
• Clinical Site — Fort Lauderdale, Florida, United States
• Clinical Site — Jacksonville, Florida, United States
• Clinical Site — Orlando, Florida, United States
• Clinical Site — Decatur, Georgia, United States
• Clinical Site — Boston, Massachusetts, United States
• Clinical Site — Berlin, New Jersey, United States
• Clinical Site — Austin, Texas, United States
• Clinical Site — Burgas, Bulgaria
• Clinical Site — Kazanlak, Bulgaria
• Clinical Site — Pleven, Bulgaria
• Clinical Site — Rousse, Bulgaria
• Clinical Site — Tsarev Brod, Bulgaria
• Clinical Site — Veliko Tarnovo, Bulgaria
• Clinical Site — Veliko Tarnovo, Bulgaria
• Clinical Site — Vratsa, Bulgaria
• Clinical Site — Brno, Czechia
• Clinical Site — Brno, Czechia
• Clinical Site — Toms River, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.